With a 2012 market value of US $4.2 billion—and expected to grow 2% per year – the Czech Republic’s pharmaceutical market is one of the most attractive markets in Central and Eastern Europe.
The country’s high-quality infrastructure, the availability of cost-effective skilled labour and regulations in sync with the EU are the primary explanations for the Czech pharmaceutical industry’s growth. There are around 8,200 registered pharmacies in the Czech Republic, with the two most well-known retail chains being Dr Max and Lloyd’s.
Generic medicines make up more than 50% of the total market share, while OTCs comprise 23% (though there was an increase to 24% in 2011). This is considered one of the biggest growth numbers in Europe. Projections for growth in the economic, demographic, health expenditure and pharmaceutical market indicators are very positive for the Czech Republic, making it a very promising and stable Emerging Market.